Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

53.54 -1.09 (-2.00%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna Inc

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
Jabil Posts Upbeat Earnings, Joins Moderna, Rivian Automotive And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Nasdaq Composite gaining around 75 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is SOFI Stock Up Today?
SoFi Technologies stock is up on Thursday as investors celebrate news that the Federal Reserve won't increase interest rates. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Opendoor (OPEN) Stock Jumps on Analyst Upgrade
Opendoor Technologies stock is rising higher on Thursday as investors in OPEN shares react to an upgrade from Keefe, Bruyette & Woods. 
Via InvestorPlace
2 Big Stocks Making Big Moves Thursday
One is rising while the other's on the decline. Here's why. 
Via The Motley Fool
Why Is Moderna (MRNA) Stock Up 11% Today?
Moderna stock is on the rise Thursday as investors in MRNA react to positive results from a skin cancer vaccine in a Phase 2b trial. 
Via InvestorPlace
What's Going On With Moderna (MRNA) Stock?
Moderna Inc (NASDAQ: MRNA) shares are trading lower by 4.5% to $74.50 during Wednesday's session. 
Via Benzinga
Moderna's Options Frenzy: What You Need to Know
Via Benzinga
Here's How Much You Would Have Made Owning Moderna Stock In The Last 5 Years
Via Benzinga
Moderna Stock Is Soaring Today - Here's Why
Moderna Inc (NASDAQ: MRNA) and Merck & Co Inc (NYSE: MRK) announced follow-up data from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study of mRNA-4157 (V940), an investigational individualized... 
Via Benzinga
Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following
Via ACCESSWIRE
Stocks Hold Steady, Yields Decline As Fed Meeting Looms: What's Driving Markets Wednesday?
Midway through the trading day on Wall Street, calm reigns supreme as investors eagerly await the Federal Reserve’s decision on interest rates. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Pfizer Issues FY24 Forecast, Joins Target Hospitality, Southwest Airlines And Other Big Stocks Moving Lower On Wednesday
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 40 points on Wednesday. Shares of Pfizer Inc. (NYSE: PFE) shares fell sharply during Wednesday’s session after the company... 
Via Benzinga
Topics Stocks
Exposures US Equities
Peering Into Moderna's Recent Short Interest
Via Benzinga
Analyst Expectations for Moderna's Future
Via Benzinga
Pfizer Stock Tumble Steepens As Seagen Guidance Update Disappoints
Pfizer's updated 2024 revenue figures, including Seagen, undercut the consensus target. 
Via Investor's Business Daily
3 Dirt-Cheap Stocks to Buy Hand Over Fist Before the End of the Year
These players could lift your portfolio when they rebound and over the long term. 
Via The Motley Fool
What's Going On With Moderna Stock Today?
Moderna Inc (NASDAQ: MRNA) announced changes to its operating model to bring focus to its short- and  
Via Benzinga
Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
Via ACCESSWIRE
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
These 2 Stocks Are All-Stars in the Making
These exciting players look cheap today considering their future prospects. 
Via The Motley Fool
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?
The big biotech's shares have been on the rise this year. 
Via The Motley Fool
7 F-Rated Stocks to Sell in December
If you’re holding F-rated stocks to sell, it may be too late to salvage 2023, but you can still get back on track toward achieving your goals. 
Via InvestorPlace
S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analysts Targets
Fifty-six percent of S&P 500 companies have shown positive performance in 2023 and 44% retreated Moderna Inc. (NASDAQ: MRNA) offers the highest upside potential (58%). 
Via Benzinga
Topics Stocks
Exposures US Equities
Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event
Via ACCESSWIRE
2024's Potential Stock Surprises: Goldman Sachs Unveils S&P 500 Laggards For Major Gains
Investors hunt for new opportunities in stocks that have been discounted & now present promising options for recovery. 
Via Benzinga
Topics Stocks
Exposures US Equities
3 Dirt Cheap Stocks You'll Regret Not Buying Before the New Year
Load up on these stocks while the price is right, and hold them for the long term. 
Via The Motley Fool
Where Will Vertex Pharmaceuticals Be in 10 Years?
Vertex shares have soared 400% over the past decade. 
Via The Motley Fool
Texas Attorney General Alleges Pfizer Misled Public on COVID-19 Vaccine Efficacy
Texas Attorney General Ken Paxton has filed a lawsuit against Pfizer Inc (NYSE: PFE), alleging the pharmaceutical giant misrepresented the efficacy of its widely- 
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
Texas Sues Pfizer For "Misrepresenting COVID-19 Vaccine Efficacy" And "Conspiring To Censor Public Discourse"
The Texas attorney general is suing pharmaceutical giant Pfizer for misrepresenting the effectiveness of the company's Covid-19 
Via Talk Markets
Topics Lawsuit
Exposures COVID-19 Financial Legal
Upwork underscores the strength of the AI gig economy
Upwork has been pursuing its goal of being the world's preeminent destination for artificial intelligence (AI) related talent and freelancers 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.